Analytical Data
-
Gene name
MHCA
- Application
-
Alternative Names
HLA-A; HLAA; MHC-A; Leukocyte Antigen A; HLA class I histocompatibility antigen, A-31 alpha chain
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P16189
-
Expression Region
Gly25~Val365
-
Molecular Weight
60kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of microtubule-associated protein (MAP) Homologous Centromeric Protein A (MHCA) recombinant protein has gained significance in the field of cellular and molecular biology due to its crucial role in regulating microtubule dynamics and ensuring proper chromosome segregation during cell division. As an important component of the mitotic spindle, MHCA is involved in the organization and stabilization of microtubules, which are essential for maintaining cell structure and function. Abnormalities in MHCA expression or function can lead to mitotic errors, contributing to various diseases, including cancer. Researchers are increasingly interested in the potential therapeutic applications of MHCA, as it may serve as a biomarker for certain malignancies or as a target for innovative drug development. By developing recombinant proteins of MHCA, scientists aim to elucidate its structural and functional properties, enabling a deeper understanding of its role in cellular processes. The production of recombinant MHCA allows for enhanced studies of its interactions with other cellular components, aiding in the identification of pathways that could be leveraged for therapeutic purposes. Furthermore, the ability to manipulate this protein in a laboratory setting opens avenues for investigating the mechanisms underlying microtubule-associated diseases, underscoring the importance of ongoing research in this area to develop effective interventions and treatment strategies. Overall, the investigation of MHCA recombinant protein is not only pivotal for basic scientific understanding but also holds promise for translational research aimed at addressing significant health challenges.
